October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
|Articles|September 2, 2016
Pharmacy Week in Review: September 2, 2016
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more. Our Week in Review is a can't miss for the busy pharmacy professional.
Advertisement
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more. Our Week in Review is a can’t miss for the busy pharmacy professional.
Advertisement
Related to this article
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
2
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
3
Ribociclib Survival Data Anchor a Sobering ESMO 2026 for Breast Cancer
4
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
5